Table 2 Analysis of main effects using MMRM for PHQ-9 score at week 6, with the delayed treatment as the control arm
Triala | Component | n | Change scores from baseline of the PHQ-9 | Differences in change scores of the PHQ-9 at week 6 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Estimated least squares mean changeb | Effect sizec | Estimated least squares mean difference | Effect sizec | P value | ||||||||
Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 6 | ||||||
Trial 1 | BAd | |||||||||||
Present | 656 | −1.47 | −1.98 | −2.23 | −2.43 | −2.51 | −2.89 | −1.07 (−1.37 to −0.77) | −1.28 (−1.62 to −0.93) | −0.38 (−0.48 to −0.27) | 5.3 × 10−13 | |
Absent | 656 | −0.70 | −1.00 | −1.29 | −1.44 | −1.69 | −1.62 | −0.60 (−0.90 to −0.30) | – | – | ||
Trial 1 | CR | |||||||||||
Present | 657 | −1.27 | −1.81 | −2.15 | −2.29 | −2.36 | −2.71 | −1.00 (−1.30 to −0.70) | −0.90 (−1.25 to −0.56) | −0.27 (−0.37 to −0.16) | 2.9 × 10−7 | |
Absent | 655 | −0.90 | −1.16 | −1.37 | −1.58 | −1.84 | −1.80 | −0.67 (−0.97 to −0.37) | – | – | ||
Trial 2 | PS | |||||||||||
Present | 657 | −1.41 | −2.05 | −2.33 | −2.34 | −2.69 | −3.08 | −1.14 (−1.40 to −0.88) | −0.91 (−1.25 to −0.57) | −0.27 (−0.37 to −0.17) | 1.8 × 10−7 | |
Absent | 655 | −1.35 | −1.85 | −1.73 | −1.99 | −2.00 | −2.17 | −0.81 (−1.07 to −0.55) | – | – | ||
Trial 3 | AT | |||||||||||
Present | 656 | −1.34 | −2.05 | −2.32 | −2.58 | −2.76 | −3.06 | −1.13 (−1.44 to −0.81) | −0.87 (−1.22 to −0.51) | −0.24 (−0.34 to −0.14) | 2.2 × 10−6 | |
Absent | 655 | −1.36 | −1.71 | −1.76 | −2.11 | −2.21 | −2.19 | −0.81 (−1.12 to −0.50) | – | – | ||
Trial 4 | BIe | |||||||||||
Present | 627 | −2.10 | −2.52 | −2.68 | −3.01 | −3.08 | −3.38 | −1.29 (−1.58 to −0.99) | −0.94 (−1.30 to −0.58) | −0.27 (−0.37 to −0.16) | 3.8 × 10−7 | |
Absent | 624 | −1.78 | −1.95 | −1.98 | −2.21 | −2.40 | −2.44 | −0.93 (−1.23 to −0.64) | – | – |